Nonhormonal Alternatives for the Treatment of Hot Flashes

Pharmacotherapy

Volumn 24, Issue 1, 2004, Pages 79-93

  Sicat, Brigitte L ^a   Brokaw, Deborah K ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Hot flashes; Literature review; Menopause; Nonhormonal treatment; Tamoxifen

Indexed keywords

AROMATASE INHIBITOR; CLONIDINE; FLUOXETINE; GABAPENTIN; PAROXETINE; RALOXIFENE; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; VENLAFAXINE;

ANOREXIA; BREAST CANCER; CLINICAL TRIAL; CONSTIPATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; FATIGUE; HEADACHE; HORMONAL THERAPY; HOT FLUSH; HUMAN; INSOMNIA; MENOPAUSE; MOOD DISORDER; NAUSEA; NERVOUSNESS; RASH; REVIEW; SCORING SYSTEM; SOMNOLENCE; SWEATING; XEROSTOMIA;

COMPLEMENTARY THERAPIES; FEMALE; HOT FLASHES; HUMANS; META-ANALYSIS;

EID: 0346096727     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.1.79.34812     Document Type: Review

References (55)

1. Bachman GA. Vasomotor flushes in menopausal women. Am J Obstet Gynecol 1999;180:S312-16.
2. Berg G, Gottqall T, Hammar M, Lindgren R. Climacteric symptoms among women aged 60-62 in Linkoping, Sweden, in 1986. Maturitas 1988;10:193-9.
3. Love RR, Cameron L, Connell BL, Leventhal H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991;151:1842-7.
4. Notelovitz M, Lenihan JP, McDermott M, Kerber IJ, Nanavati N, Arce J. Initial 17β-estradiol dose for treating vasomotor symptoms. Obstet Gynecol 2000;95:726-31.
5. McNagny SE. Prescribing hormone replacement therapy for menopausal symptoms. Ann Intern Med 1999;131:605-16.
6. O'Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001;93:754-62.
7. Col NF, Hirota LK, Orr RK, Erban JK, Wong JB, Lau J. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol 2001;19:2357-63.
8. Loprinzi CL, Barton DL, Rhodes D. Management of hot flashes in breast-cancer survivors. Lancet Oncol 2001;2:199-204.
9. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002;288:321-33.
10. Hulley S, Grady D, Bush T, et al, for the Heart and Estrogen/ Progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
11. Grady D, Herrington D, Bittner V, et al, for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002;288: 49-57.
12. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345:1243-9.
13. U.S. Preventive Task Force. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale. Ann Intern Med 2000;137:834-9.
14. North American Menopause Society. Amended report from the NAMS advisory panel on postmenopausal hormone therapy. Menopause 2003;10:6-12.
15. Kirschstein R. Menopausal hormone therapy: summary of a scientific workshop. Ann Intern Med 2003;138:361-4.
16. Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 1998;16:495-500.
17. Bergmans MG, Merkus JM, Corbey RS, Schellekens LA, Ubachs JM. Effect of Bellergal Retard on climacteric complaints: a double-blind, placebo-controlled study. Maturitas 1987;9:227-34.
18. Nesheim BI, Saetre T. Reduction of menopausal hot flushes by methyldopa. Eur J Clin Pharmacol 1981;20:413-16.
19. Casper RF, Yen SSC. Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism. Clin Endocrinol 1985;22:293-312.
20. Freedman RR, Norton D, Woodward S, Cornelissen G. Core body temperature and circadian rhythm of hot flashes in menopausal women. J Clin Endocrinol Metab 1995;80:2354-8.
21. Freedman RR. Biochemical, metabolic, and vascular mechanisms in menopausal hot flashes. Fertil Steril 1998;70:322-7.
22. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002;77:1207-18.
23. Berendsen H. The role of serotonin in hot flushes. Maturitas 2000;36:155-64.
24. Goldberg RM, Loprinzi CL, O'Fallon JR, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994;12:155-8.
25. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet 2000;356:2059-63.
26. Center for Drug Evaluation and Research. Guidance for industry. Estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms: recommendations for clinical evaluation, 2003. Available from http://www.fda.gov/cder/guidance/5412dft.doc. Accessed September 2, 2003.
27. Clayden JR, Bell JW, Pollard P. Menopausal flushing: a double-blind trial of a non-hormonal medication. Br Med J 1974;1:409-12.
28. Edington RF, Chagnon JP, Steinberg WM. Clonidine (Dixarit) for menopausal flushing. Can Med Assoc J 1980;123:23-6.
29. Laufer LR, Erlik Y, Meldrum DR, et al. Effect of clonidine on hot flashes in postmenopausal women. Obstet Gynecol 1982;60:583-6.
30. Lindsay R, Hart DM. Failure of response of menopausal vasomotor symptoms to clonidine. Maturitas 1978;1:21-5.
31. Wren BG, Brown LB. A double-blind trial with clonidine and a placebo to treat hot flushes. Med J Aust 1986;144:369-70.
32. Salmi T, Punnonen R. Clonidine in the treatment of menopausal symptoms. Int J Gynaecol 1982;60:583-6.
33. Nagamani M, Kelver ME, Smith ER. Treatment of menopausal hot flashes with transdermal administration of clonidine. Am J Obstet Gynecol 1987;156:561-5.
34. Bolli P, Simpson FO. Clonidine in menopausal flushing: a double-blind trial. N Z Med J 1986;144:369-70.
35. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Eng J Med 1989;320:479-84.
36. Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center community oncology program study. Ann Intern Med 2000;132:788-93.
37. Horst DW, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord 1998;51:237-54.
38. Loprinizi CL, Pisansky TM, Fonseca R, et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998;16:2377-81.
39. Sloan JA, Loprinzi CL, Kuross SA, et al. Randomized comparison of four tools measuring quality of life in patients with advanced cancer. J Clin Oncol 1998;16:3662-73.
40. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: 25 years of evaluation. Clin Psychol Rev 1988;8:77-100.
41. Barton D, LaVasseur B, Loprinzi C, Novotny P, Wilwerding M, Sloan J. Venlafaxine for the control of hot flashes: results of a longitudinal continuation study. Oncol Nurs Forum 2002;29:33-40.
42. Stearns V, Isaacs C, Rowland J, et al. A pilot trial assessing the efficacy of paroxetine (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 2000;11:17-22.
43. Weitzner MA, Moncello J, Jacobsen PB, Minton S. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. J Pain Symptom Manage 2002;23:337-45.
44. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes. JAMA 2003;289:2827-34.
45. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002: 1578-83.
46. Guttuso TJ. Gabapentin's effects on hot flashes and hypothermia. Neurology 2000;54:2161-3.
47. Loprinzi CL, Barton DL, Sloan JA, et al. Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin Proc 2002; 77:1159-63.
48. Thummala AR, Griggs J, Rosenblatt J, et al. Pilot study using gabapentin on tamoxifen-induced hot flashes in women with breast cancer [abstr]. Proc Am Soc Clin Oncol 2002;21:362a.
49. Guttuso T, Kurlan R, McDermott MP, Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003;101: 337-45.
50. Ware J Jr, Snow K, Konsinski M, Gandek B. SF-36 health survey: manual and interpretation guide. Boston: The Health Institute, New England Medical Center, 1993.
51. McNair D, Lorr M, Droppleman L. Profile of mood states: manual. San Diego: Educational and Industrial Testing Service, 1981.
52. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998;280:1831-6.
53. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28: 193-213.
54. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997. JAMA 1998;280:1569-75.
55. Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 2002;137:805-13.